Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Background
Active Hexose Correlated Compound is assumed to have a positive effect on immunity, including induce a phagocytic response, reduce tumor resistance, and cytokine response including interferon-gamma and interleukins. Tuberculosis patients with concurrent Human immunodeficiency Virus (HIV) might have benefit when receiving active hexose compound during tuberculosis treatment
Purposes
Methods A clinical trial involving patients with Tuberculosis-HIV infection
Hypothesis
Population :
Lung Tuberculosis patient with HIV Infection
Design :
Double-Blind Randomized Control Trial at the outpatient setting
Randomization Simple Randomization
Proposed Number of participants :
Using the difference between two independent means of duration to sputum conversion
Proposed analysis
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active Hexose Correlated Compound | Experimental | The participants will be given Active Hexose Correlated Compound as a capsule 3 gram/ daily for 6 months |
|
| Control Group | No Intervention | Participant will be given only the tuberculosis and antiretroviral treatment |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Active Hexoses Correlated Compound | Dietary Supplement | Active Hexose Correlated Compound was isolated from basidiomycetes which comprise polysaccharides and amino acids. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Sputum Conversion Duration | Sputum conversion duration defined as the duration to change positive result in sputum smear into negative results. The sputum smear level using Ziehl Neelsen ranging from Negative to 3+. | six month after the intervention started |
| Chest X-Ray Extension | Distribution of active tuberculosis feature in Chest X-Ray including number of consolidation and cavitation | Changes of number of active tuberculosis feature from baseline to 6 months |
| Interleukin 6 Level | Value of Interleukin 6 in blood Sample | Changes of Interleukin 6 Level from baseline to 6 months |
| Interleukin 10 Level | Value of Interleukin 10 in blood Sample | Changes of Interleukin 10 value from baseline to 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Cluster Differentiation 4 (CD4) cells value | Cluster Differentiation 4 (CD4) cells value in blood sample | Changes of Cluster Differentiation 4 (CD4) cells value from baseline to 6 months |
| Cluster Differentiation 8 (CD8) cells value |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Djamaludin Ma'dolangan, MD | Hasanuddin University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Labuang Baji General Hospital | Makassar | South Sulawesi | 90132 | Indonesia |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| Background | Matar, C., Graham, E. 2017. Immune Modulatory Function. Clinician's Guide To AHCC, Evidence-Based Nutritional Immunotherapy, Edited by Anil D.K, Philip, C and Toshinori Ito. P.54-61. | ||
| 28440968 | Background | Suknikhom W, Lertkhachonsuk R, Manchana T. The Effects of Active Hexose Correlated Compound (AHCC) on Levels of CD4+ and CD8+ in Patients with Epithelial Ovarian Cancer or Peritoneal Cancer Receiving Platinum Based Chemotherapy. Asian Pac J Cancer Prev. 2017 Mar 1;18(3):633-638. doi: 10.22034/APJCP.2017.18.3.633. | |
| 19699163 |
Not provided
Not provided
There is no plan to share individual participant data including de-identified data and protocol
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014376 | Tuberculosis |
| D000163 | Acquired Immunodeficiency Syndrome |
| ID | Term |
|---|---|
| D009164 | Mycobacterium Infections |
| D000193 | Actinomycetales Infections |
| D016908 | Gram-Positive Bacterial Infections |
| D001424 | Bacterial Infections |
Not provided
Not provided
One group will be given Active Hexose Correlated Compound as adjuvant and the comparison group will only receive the tuberculosis treatment
Not provided
Not provided
Investigator will be blinded from the allocation (not allowed to observe the allocation and intervention) and the outcome assessor will not be informed the code of allocation
Cluster Differentiation 8 (CD8) cells value in blood sample
| Changes of Cluster Differentiation 8 (CD8) cells value from baseline to 6 months |
| Background |
| Sun B, Wakame K, Sato E, Nishioka H, Aruoma OI, Fujii H. The effect of active hexose correlated compound in modulating cytosine arabinoside-induced hair loss, and 6-mercaptopurine- and methotrexate-induced liver injury in rodents. Cancer Epidemiol. 2009 Oct;33(3-4):293-9. doi: 10.1016/j.canep.2009.07.006. Epub 2009 Aug 20. |
| 18791928 | Background | Terakawa N, Matsui Y, Satoi S, Yanagimoto H, Takahashi K, Yamamoto T, Yamao J, Takai S, Kwon AH, Kamiyama Y. Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: a double-blind, placebo-controlled trial. Nutr Cancer. 2008;60(5):643-51. doi: 10.1080/01635580801993280. |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| D015658 | HIV Infections |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D015229 | Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012897 | Slow Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |